NCT02253394View on ClinicalTrials.gov

The Combination Ambrisentan Plus Spironolactone in Pulmonary Arterial Hypertension Study

PHASE4TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Ambrisentan plus Spironolactone

Cardiopulmonary fitness

DRUG

Ambrisentan plus Placebo

Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness

Trial Locations (1)

02115

Brigham & Women's Hospital, Boston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Brigham and Women's Hospital

OTHER